Dr Oliver Planz

Institute of Immunology, University of Tübingen, Tübingen, Germany

Prof. Oliver Planz, Ph.D., is an esteemed expert in Translational Immunology of Infection, currently leading research initiatives at the Institute of Immunology, University of Tübingen. With a robust background in viral immunology, Prof. Planz has dedicated his career to advancing our understanding of immune responses to infections and developing innovative antiviral therapies.

Prof. Planz's career began with a Ph.D. in Viral Immunology from the Institute of Virology, University of Giessen, Germany, where he cultivated a deep expertise in pathogen-host interactions. His postdoctoral training at the University of Zürich under the mentorship of Nobel Laureate R.M. Zinkernagel further honed his focus on infection immunology, setting the stage for his contributions to the field.

Since then, Prof. Planz has held several positions, including leading the "Immunology and Cell Biology" research unit at the Friedrich-Loeffler-Institute in Tübingen. He became an Associate Professor at the Eberhard-Karls University of Tübingen and subsequently assumed his current role, where he directs translational research to bridge basic immunological discoveries with clinical applications. His work emphasizes antiviral drug development, exemplified by his co-founding of Atriva Therapeutics GmbH in 2016, aimed at novel influenza therapeutics.

Prof. Planz is actively involved in global initiatives on antiviral drug development. His contributions extend to various Phase 1 and Phase 2 clinical trials, showcasing his commitment to bringing innovative solutions to public health challenges. He is a member of several professional societies, serves on editorial boards and holds various patent families.

His work is widely recognized, underscoring his influence in virology and immunology research. Prof. Planz continues to inspire the scientific community through his mentorship and entrepreneurship in the field of infectious diseases.

Updated 13 November 2024